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1. Introduction 
 
Community-acquired pneumonia (CAP) is defined as an acute infection of the 
pulmonary parenchyma that is associated with at least some symptoms of acute in-
fection, a new infiltrate on chest x-ray or auscultatory findings such as altered breath 
sounds and/or localized rales in community-dwelling patients (Infectious Diseases 
Society of America 2000).  It is a common condition that carries a high burden of 
mortality and morbidity, particularly in elderly populations.  Although most patients 
recover without sequellae, CAP can take a very severe course, requiring admission 
to an intensive care unit (ICU) and even leading to death.  According to US data, it is 
the most important cause of death from infectious causes and the sixth most impor-
tant cause of death overall (Adams et al. 1996).  Even though the mortality from 
pneumonia decreased rapidly in the 1940s after the introduction of antibiotic therapy, 
it has remained essentially unchanged since then or has even increased slightly 
(MMWR 1995). 
Furthermore, significant costs are associated with the diagnosis and manage-
ment of CAP.  Between 22% and 42% of adults with CAP are admitted to hospital, 
and of those, 5% to 10% need to be admitted to an ICU (British Thoracic Society 
2001).  In the US, it is estimated that the total cost of treating an episode of CAP in 
hospital is about USD $ 7500, which is approximately 20 times more than the cost of 
treating a patient on an outpatient basis (Lave et al. 1999).  CAP also contributes 
significantly to antibiotic use, which is associated with well-known problems of resis-
tance.   
In treating patients with CAP, the choice of antibiotic is a difficult one.  Factors 
to be considered are the possible etiologic pathogen, the efficacy of the substance, 
potential side-effects, the treatment schedule and its effect on adherence to treat-
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ment as well as the particular regional resistance profile of the causative organism 
and the co-morbidities that might influence the range of potential pathogens (such as 
in cystic fibrosis) or the dosage (as in the case of renal insufficiency).  Although many 
studies have been published concerning CAP and its treatment, there is no concise 
summary of the available evidence and only few guidelines (British Thoracic Society 
2001, American Thoracic Society 2001, Canadian Community-Acquired Pneumonia 
Working Group 2000, Infectious Diseases Society of America 2000) that can help 
clinicians in choosing the most appropriate antibiotic.  The applicability of such guide-
lines is furthermore limited by wide variations in regional resistance profiles and by 
their focus on hospitalized patients.  
 
1.1 Framework of the review:  the Cochrane Collaboration 
 
This review addresses the treatment of community-acquired pneumonia (CAP) 
in adolescent and adult outpatients.  It was conducted within the framework of the 
Cochrane Collaboration, a worldwide network of researchers whose aim is to “pre-
pare, maintain and promote the accessibility of systematic reviews of the effects of 
health care interventions” (see www.cochrane.org, www.cochrane.de) using the evi-
dence available from randomized controlled trials (RCT).  Reviews are initiated by 
researchers with an interest in a particular clinical question.  A protocol in which the 
goals and methods of the review are described is then written and published in elec-
tronic form in the Cochrane Library (accessible for a fee at www.cochranelibrary.net).  
The review is then carried out independently by at least two reviewers who may be 
assisted by others, particularly when initially screening study reports for inclusion into 
the study.  Having reached their own individual conclusions about which studies to 
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include in the review, the two reviewers compare their results and resolve any differ-
ences by discussion and consensus.  One or both of the reviewers then proceeds to 
analysing the data of the selected studies and writing the final review.  The review 
then undergoes peer review within the framework of the Cochrane Collaboration and 
is published as a citable peer-reviewed publication in the Cochrane Library of Sys-
tematic Reviews (accessible for a fee at www.cochranelibrary.net).   
In order to disseminate the results of reviews more broadly and to circumvent 
the problems arising from the fact that the Cochrane Library is only accessible to pay-
ing subscribers, the Lancet has recently made a commitment to publishing Cochrane 
Reviews and has encouraged review authors to submit their reviews for publication in 
the Lancet (Clark and Horton 2001). 
 
1.2 Statement of authorship 
 
This review was initiated and published as a Cochrane protocol by Prof. Mi-
chael Kochen (MMK) in collaboration with other colleagues from the UK and the 
Netherlands, in particular Prof. Theo JM Verheij (TJMV) of Utrecht University (Verheij 
2001).  MMK co-wrote the protocol and screened abstracts and full articles for inclu-
sion into the review.  TJMV co-wrote the protocol, screened abstracts and full articles 
for inclusion into the study and decided, in agreement with me, which articles to in-
clude into the review. 
As the main reviewer, I carried out a review of the background literature, 
screened abstracts and full articles for inclusion into the study, decided, in conjunc-
tion with TJMV, which articles to include, extracted the data from these articles, per-
formed the quantitative analyses and wrote the text, tables and figures of the review.   
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The present dissertation is a report of the work that I carried out myself and is 
not the final text of the Cochrane review, which is less extensive in both scope and 
length.  In particular, the literature review included in the present dissertation is much 
more extensive.  Furthermore, the efficacy analyses as well as all the data pertaining 
to the open-label studies are unique to this dissertation.  Except for discussions with 
TJMV concerning the choice of studies to be included into the review, I have carried 
out this study independently.  As such, I take full responsibility for the contents of this 
study as well as for any shortcomings or errors that may remain. 
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2. Background and literature review 
 
2.1 Community-acquired pneumonia 
2.1.1 Incidence 
 
In the industrialized world, the annual incidence of CAP in community-
dwelling adults is estimated at 5 to 11 cases per 1000 adult population (British Tho-
racic Society 2001).  The incidence is known to vary markedly with age, being higher 
in the very young and the elderly.  In one Finnish study, the annual incidence for 
people aged 16-59 years was 6 cases per 1000 population, for those 60 years and 
older it was 20 per 1000, and for people aged 75 and over, 34 per 1000 (Jokinen et 
al. 1993).  Annual incidences of 30-50 per 1000 population have been reported for 
infants below 1 year of age (Marrie 2001).  Seasonal variations in incidence are also 
significant, with a peak in the winter months (Marrie 2001).   
The annual incidence of CAP requiring hospitalisation has been estimated at 
1 to 4 patients per 1000 population (Marrie 1990, Fine et al. 1996).  The proportion of 
patients requiring hospitalisation varies from country to country and across studies 
and has been estimated as ranging anywhere between 15% and 56% (Foy et al. 
1973, Minogue et al. 1998).  Of those, 5% to 10% required admission to an intensive 
care unit (ICU) (British Thoracic Society Research Committee and Public Health 
Laboratory Service 1992, Torres et al. 1991).  Conversely, about 8% to 10% of ad-
missions to a medical ICU are due to severe CAP (Woodhead et al. 1985). 
 
 
 
10
 
 
2.1.2 Etiology 
 
More than 100 microorganisms have been identified so far as potential causa-
tive agents of CAP (Marrie 2001).  They can be classified according to their biological 
characteristics as either bacteria, mycoplasma and other intracellular organisms, vi-
ruses, fungi and parasites.  The most common causative agent of CAP is the bacte-
rium Streptococcus pneumoniae, which is implicated in 20% to 75% of cases of CAP 
(Marrie 2001) and about 66% of bacteremic pneumonia (Infectious Diseases Society 
of America 2000).  Another causative bacterium is Haemophilus influenzae.  So-
called “atypical” organisms have also been implicated as causal agents.  These in-
clude Chlamydia pneumoniae, Mycoplasma pneumoniae and Legionella pneumo-
phila (Marrie 2001).   
Influenza is the most common serious viral pathogen causing airway infections 
in adults (Infectious Diseases Society of America 2000).  Although it does not itself 
cause pneumonia, its most common serious complication is bacterial superinfection, 
usually due to Streptococcus pneumoniae.  Affected patients are primarily older than 
65 years and/or residents of chronic care facilities.  Effective prevention is possible 
through yearly vaccination of populations at risk and should include vaccination of 
those who care for such patients (Potter et al. 1997). 
The identification of the causal organism is a challenging task:  since lung tis-
sue cannot be routinely obtained, clinicians must rely on sputum samples – which 
can only be obtained successfully in about 33% of patients – or on blood cultures, 
that are positive in only 6% to 10% of patients with CAP (Canadian Community-
Acquired Pneumonia Working Group 2000).  Furthermore, it takes a minimum of 2 to 
3 working days to obtain culture results, be it from sputum samples or blood.  Conse-
quently, it is often necessary to initiate therapy on empiric grounds alone.  Further-
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more, routine surveillance of samples sent to microbiology labs by primary care phy-
sicians does not provide an accurate picture of the actual situation in the community, 
as samples are often sent only when a first, empirical therapeutic attempt has failed. 
 
2.1.3 Risk factors 
 
A variety of risk factors predisposing a patient to CAP have been identified.  
These include host factors, such as chronic obstructive pulmonary disease (COPD), 
alcoholism or immune suppression, environmental factors, such as exposure to cer-
tain animals, for example parrots (Chlamydia psittaci), parturient cats and sheep 
(Coxiella burnetii), and rabbits (Francisella tularensis), recent hotel stay (Legionella 
pneumophila), travel abroad or in endemic regions (Coccidioides immitis, Histo-
plasma capsulatum), and occupational factors, such as contact with body fluids con-
taining infective agents (Mycoplasma tuberculosis) (Canadian Community-Acquired 
Pneumonia Working Group 2000).  Smoking is also thought to be an important risk 
factor for acquiring CAP (Marrie 2001).  As outlined above, a number of risk factors 
are related to particular causative organisms and enquiring about their presence may 
improve diagnostic accuracy with respect to the etiologic agent, however the British 
Thoracic Society (2001) cautions that due to the low frequency of some of these or-
ganisms in patients with CAP and the high frequency of the risk factors for exposure 
to these organisms in the population, routine questioning about such risk factors may 
be misleading. 
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2.1.4 Diagnosis 
 
The diagnosis of CAP remains a challenge for clinicians.  There is no single 
finding that is pathognomonic of CAP, and even the gold-standard chest x-ray may 
fail to provide the necessary information to make the correct diagnosis.  However, 
there is good evidence supporting the view that the diagnosis of CAP is inaccurate 
without a chest x-ray (British Thoracic Society 2001).   
It is important to differentiate between CAP and other lower respiratory tract in-
fections, such as acute bronchitis, and to differentiate between these entities and 
other potential causes of similar symptom complexes, such as pulmonary neoplasia, 
congestive heart failure or pulmonary embolism, as the subsequent management of 
such patients differs greatly.  Most cases of upper respiratory tract infections and 
acute bronchitis are caused by viruses, and therefore do not require antibiotic treat-
ment (Infectious Diseases Society of America 2000).  The use of antibiotics in such 
cases is inappropriate and should be avoided. 
Despite the importance accorded to history, physical examination, chest x-rays 
and some laboratory investigations in the assessment of patients suspected of hav-
ing CAP, only very few studies have attempted to assess the validity of such ap-
proaches (Canadian Community-Acquired Pneumonia Working Group 2000).  Fur-
thermore, none of these studies relied on autopsies as a diagnostic gold standard.  
Instead, they used chest x-rays or even clinical suspicion to decide whether pneumo-
nia was present, thus making the validity of their conclusions highly questionable. 
Another factor that further complicates the diagnosis of CAP are inter-observer 
variations in the identification of symptoms and signs in patients suspected of having 
CAP.  The reliability of physical signs has been studied and found to be highly vari-
able (Spiteri et al. 1988, Schilling et al. 1955).  As for symptoms, inter-observer reli-
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ability has not been studied, but it is known from studies of other respiratory condi-
tions that there is significant variation between observers (Cochrane et al. 1951, 
Fletcher 1964). 
Recently, a urine test for rapid detection of Streptococcus pneumoniae has 
been approved by the American Food and Drug Administration (FDA) (Henney 
1999).  The test can be carried out in the physician’s office or in the emergency room, 
requires only 5 ml of urine and results are available within 15 minutes.  The test is 
reported to have a sensitivity of 86% to 90% and a specificity of 71% to 94%.  It is 
intended as an adjunct to the usual clinical, laboratory and radiological investigations 
for suspected CAP.  Whether it will become part of the diagnostic armamentarium in 
actual practice remains to be seen. 
Consequently, the diagnosis of CAP should be made based on a combination 
of physical, laboratory, microbiologic and radiographic findings, keeping in mind that 
none of them is perfectly reliable for diagnosis (Canadian Community-Acquired 
Pneumonia Working Group 2000). 
 
2.1.5 Treatment 
 
Since the majority of cases CAP are caused by organisms amenable to treat-
ment with an antibiotic drug, rapid initiation of antibiotic treatment is indicated in the 
vast majority of cases.  Difficulties arise when a clinician is confronted with the need 
to choose an antibiotic drug for a particular patient.  The appropriate choice of antibi-
otic for the ambulatory treatment of CAP in adults and adolescents is the focus of the 
present study and I will attempt to provide an answer to this question on the basis of 
the currently available evidence. 
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2.1.5.1 Antibiotic resistance 
 
The problem of antibiotic resistance has received increasing attention in recent 
years.  The problem is not confined to community-acquired pneumonia, however, 
since CAP can take a very severe course even leading to death, it is a condition for 
which the issue of antibiotic resistance takes on even greater importance. 
Traditionally, the preferred antimicrobial agent for the treatment of Streptococ-
cus pneumoniae was penicillin G (Infectious Diseases Society of America 2000).  
However, widespread penicillin use for a variety of infectious conditions has lead to 
the emergence and rise of penicillin resistance.  Recent studies estimate the propor-
tion of penicillin resistant Streptococcus pneumoniae at around 25% (Marrie 2001).  
Similarly, the use of other antibiotics has led to the emergence of resistance against 
these agents in a variety of microorganisms.  For example, it is estimated that ap-
proximately 30% of Haemophilus influenzae isolates are resistant to amoxicillin (Mar-
rie 2001). 
Furthermore, the phenomenon of antibiotic resistance is subject to wide re-
gional and international variations, as access to and patterns of use of antibiotics 
vary widely. 
As is the case with the identification of pathogens, it is also difficult to estimate 
the exact prevalence of antibiotic resistance in a particular area by simple surveil-
lance of specimen sent to microbiology laboratories because these come from pre-
selected patients, some them having already failed a first empirical treatment and 
therefore being more likely to carry a resistant pathogen. 
For this reason, some practice guidelines emphasize the importance of obtain-
ing baseline microbiologic specimen – the minimum being a Gram stain, with or with-
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out culture – before initiation of empiric therapy (Infectious Diseases Society of Amer-
ica 2000). 
 
2.1.6 Prognosis 
 
The prognosis of CAP ranges from full recovery without sequellae to death on 
an intensive care unit within a few days of disease onset.  Because of this broad and 
dramatic spectrum, prognostic factors for the identification of high-risk patients have 
been the subject of much research.   
The Pneumonia Patient Outcome Research Team (Pneumonia PORT) has 
developed a clinical prediction rule to identify patients at risk of short-term mortality 
from CAP that is intended as a tool to assist clinicians in making decisions about the 
initial location and intensity of treatment (Fine et al. 1997).  This prediction rule has 
gained wide acceptance and has been included into recent clinical practice guide-
lines (Infectious Diseases Society of America 2000, Canadian Community-Acquired 
Pneumonia Working Group 2000). 
In ambulatory patients, the mortality rate from pneumonia is low, probably be-
low 1% (British Thoracic Society 2001), but some estimates go as high as 5% 
(American Thoracic Society 2001).  In hospitalized patients, it hovers around 12%, 
increasing to close to 40% (American Thoracic Society 2001) or even 50% (British 
Thoracic Society 2001) in patients requiring admission to an ICU. 
 
2.2 Practice guidelines for the treatment of community-acquired 
pneumonia  
 
In recent years, there has been an explosion in the number of clinical practice 
guidelines being produced and published.  The field of infectious diseases is no ex-
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ception, and a few guidelines for the diagnosis and treatment of community-acquired 
pneumonia have been published over the past decade.  Most recently, four major 
professional societies have updated the guidelines they had published in the early 
1990s.  These guidelines are based on a combination of literature review and expert 
opinions.  As such, they represent an attempt at synthesizing the available evidence 
and aim at providing clinicians with diagnosis and treatment strategies that are based 
as much as possible on the current state of knowledge.  In the following sections, 
these guidelines will be examined in further detail in an attempt to get an overall view 
of the current state of knowledge with respect to CAP. 
These guidelines were identified in the course of searching the literature for 
studies and reviews concerned with community-acquired pneumonia.  This was done 
using the search strategy reported in section 4.2.  No language restrictions were ap-
plied.  In an effort to broaden the search, the Internet was searched for websites list-
ing guidelines about the treatment of CAP.  This search was conducted both in Eng-
lish and in German.  No German-language guidelines could be identified using this 
search strategy.  A few German language review articles dealing with CAP were 
identified (Dusch and Täuber 2001, Gillissen and Ewig 2000 a, Gillissen and Ewig 
2000 b, Rosseau and Suttorp 2000, Ruef 2001), however these were all “secondary 
literature” article summarizing evidence from other studies and guidelines in a non-
systematic way and intended for a general medical readership. 
 
2.2.1 American Thoracic Society (2001) 
 
In 2001, the American Thoracic Society published an update of its original 
1993 statement on community-acquired pneumonia (American Thoracic Society 
2001).  These guidelines were developed by a committee composed of pulmonary, 
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critical care, infectious disease and general internal medicine specialists.  Ambulatory 
care physicians, general practitioners in particular, appear to have been left out.  This 
raises concerns that the ambulatory care perspective may have been neglected. 
The guidelines development strategy is described in detail, however there is 
no detailed account of how the literature was searched. 
The American Thoracic Society claims that its guidelines are evidence-based 
and reports using a classification system based on the system used by the Canadian 
Infectious Diseases Society and Canadian Thoracic Society in their CAP guidelines 
update (Canadian Community-Acquired Pneumonia Working Group 2000), however, 
they do not state the level of evidence for each of their therapeutic recommendations, 
nor do they give any specific references supporting those recommendations.  Finally, 
the committee reports that they focused on “studies that included an extensive diag-
nostic approach to define the etiologic pathogen” and that “most [studies] involved 
hospitalized patients” (American Thoracic Society 2001, p. 1733).  This raises con-
cerns that the evidence-base on which the recommendations for outpatients were 
made may have been insufficient. 
The new statement includes a summary of the available literature as well as 
“evidence-based recommendations for patient management” (American Thoracic So-
ciety 2001, p. 1730).    The guidelines recommend that all patients with suspected 
CAP should have a chest radiograph to confirm the diagnosis, yet they recognize that 
this may not be feasible in some ambulatory settings.  Sputum Gram stain and cul-
ture are recommended only if drug-resistant bacteria or an organism not covered by 
the usual empiric therapy are suspected.   
As for therapy and management, the Society advocates an empiric approach 
based on likely pathogens.  Patients are to be classified into one of four groups de-
18
 
 
pending on factors thought to influence the spectrum of potential pathogens, namely: 
1) the place of therapy (outpatient, inpatient regular ward, inpatient ICU), 2) the pres-
ence of cardiopulmonary disease (COPD, heart failure), and 3) the presence of modi-
fying factors, which include risk factors for drug-resistant Streptococcus pneumoniae 
(DRSP), enteric gram-negatives (nursing home residence) and Pseudomonas 
aeruginosa.  Using these factors, the guidelines define four patient groups:  1) outpa-
tients with no history of cardiopulmonary disease and no modifying factors, 2) outpa-
tients with cardiopulmonary disease and/or other modifying factor, 3) inpatients not 
admitted to the ICU; this group is further subdivided into those with and without car-
diopulmonary disease and/or other modifying factors, and 4) ICU-admitted patients, 
who are further subdivided into those with or without risk factors for Pseudomonas 
aeruginosa. 
For each group, the available evidence was reportedly combined to identify 
the most likely pathogens, and recommendations for empiric therapy were made on 
this basis.  For group 1 (outpatients without additional risk factors), the recommended 
therapy is an advanced generation macrolide, such as azithromycin or clarithromycin, 
or doxycycline.  The advanced generation macrolides were recommended on the 
grounds that erythromycin does not cover Haemophilus influenzae and is not toler-
ated as well.  In group two (outpatients with cardiopulmonary disease and/or other 
modifying factors), a combination of a beta-lactam with either one of the above-
mentioned macrolides or doxycycline is recommended.  The beta-lactams mentioned 
include cefpodoxine, high-dose amoxicillin and amoxi/clavulanate.  The combination 
treatment is advocated because amoxicillin does not offer adequate coverage for H. 
influenzae.  Furthermore, it is recommended that all patients, regardless of what 
group they belong to, should be treated for “atypical” organisms (Chlamydia pneu-
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moniae, Mycoplasma pneumoniae, Legionella species).  This is usually done by in-
cluding a macrolide antibiotic in the recommended treatment plan. 
 
2.2.2 British Thoracic Society (2001) 
 
The British Thoracic Society also recently updated its 1993 guidelines for the 
treatment of CAP in adults admitted to hospital to include patients treated in an am-
bulatory setting (British Thoracic Society 2001).  The British Thoracic Society guide-
lines committee was composed of 12 members, of which 6 were general practitio-
ners, four of them with a special interest in respiratory medicine and an “active re-
search interest” in respiratory infectious diseases.  The other members of the 
committee were a clinical microbiologist, two infectious disease specialists, a 
registrar in respiratory medicine, a clinical epidemiologist and a medical librarian.  
The search and study selection strategy employed is described in details, and a level 
of evidence is explicitly given for every recommendation made by the committee. 
The guidelines do not advocate the routine use of chest radiographs or spu-
tum culture for the majority of patients with CAP who are managed on an outpatient 
basis.  The diagnosis of CAP is to be made on clinical grounds, and severity as-
sessment is emphasized as the key to appropriate management, whether the pa-
tients are to be treated in the community or in hospital.  The choice of antibiotic 
treatment for outpatients is empiric and the main target organism remains S. pneu-
moniae.   
The authors emphasize the fact that their literature search for the period 1981-
99 yielded only 16 articles judged relevant to the antibiotic treatment of CAP and that 
few of these studies were conducted within a setting comparable to those of UK prac-
tices.  Nonetheless, and despite explicitly acknowledging that the currently available 
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evidence forms an “unsatisfactory basis” for making solid evidence-based recom-
mendations, the British Thoracic Society continues to recommend amoxicillin as the 
preferred agent on the grounds of cost, current practice, “wide experience”, safety 
and drug tolerance, but recommends a higher dose (500 mg to 1000 mg po tid) than 
used commonly in practice.  The fact that clinical treatment failures have rarely been 
documented when penicillin-resistant strains are treated with higher doses of amox-
icillin and that penicillin resistant pneumococci are still relatively rare in the UK is 
given as the rationale for recommending higher doses of amoxicillin.  Erythromycin 
(500 mg po qid) is recommended as the alternative treatment for patients who do not 
tolerate amoxicillin.  Clarithromycin (500 mg po bid) is suggested as the alternative 
agent for the sub-group of these patients who do not tolerate erythromycin, usually 
due to gastrointestinal side-effects. 
Interestingly, the guidelines committee considered tetracyclines (doxycycline) 
as an agent of first choice because resistance rates for pneumococci are lower that 
for penicillins or erythromycin and it is also active against “atypical” agents, however 
they refrained from making it a first choice recommendation in their guidelines due to 
a presumed reluctance of physicians to change their current practice that would “limit 
compliance with recommendations”.  This is an interesting example of how perceived 
inertia on the part of practitioners (whether real or only imagined by the guidelines 
committee) can significantly influence the content of practice recommendations 
(Keeley 2002). 
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2.2.3 Canadian Infectious Diseases Society / Canadian Thoracic Society 
(2000) 
 
In 2000, the Canadian Infectious Diseases Society and the Canadian Thoracic 
Society updated their 1993 guidelines for the treatment of CAP (Canadian Commu-
nity-Acquired Pneumonia Working Group 2000).  Members of the guidelines commit-
tee are listed at the end of the report, however there is no mention of the members’ 
area of specialty, so it is unclear whether physicians primarily involved in the care of 
ambulatory patients were involved in the guidelines formulation process.   
The literature search strategy is described in reasonable detail and a hierar-
chical evaluation of the strength of evidence was carried out.  Accordingly, a level of 
evidence is explicitly given for each recommendation made by the committee, unfor-
tunately these are included only in the text of the guidelines and not in the tables 
where the recommendations are also summarized.   
The committee bases its recommendations on a classification of patients ac-
cording to the place of treatment (outpatient, inpatient, nursing home).  The guide-
lines also provide a scoring system that uses objective criteria to assist physicians in 
deciding whether a patient should be hospitalized or not.   
With respect to chest radiography, the committee points out that a number of 
infectious and non-infectious conditions may present a radiographic picture that is 
indistinguishable from that of pneumonia and that only one small study has assessed 
the ability of chest radiography to detect pulmonary infiltrates in patients suspected of 
having CAP (the gold standard used was high resolution CT scanning).  They also 
point out that expert opinions are divided concerning the necessity of performing rou-
tine chest x-rays in patients suspect of having CAP.  Nonetheless, the committee 
recommends that chest x-rays be performed routinely “under most circumstances” in 
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such patients because the diagnosis of pneumonia is strengthened (although not 
confirmed) by the presence of an infiltrate. 
As for microbiological studies, no specific investigations are recommended for 
the majority of patients treated on an outpatient basis. 
For outpatients without modifying risk factors, the treatment of choice is a 
macrolide (erythromycin, azithromycin or clarithromycin), the second choice treat-
ment being doxycycline.  Outpatients with modifying factors are further subdivided 
into three groups:  those with chronic obstructive pulmonary disease (COPD) who did 
not receive antibiotics or steroids within the past 3 months, COPD patients who did 
get antibiotics or steroids within the past three months, and patients in whom 
macroaspiration is suspected (alcoholics, patients with impaired consciousness, im-
paired gag reflex or other deglutitional dysfunction).   
In the first group (COPD, no antibiotics or steroids in past 3 months), the first 
choice is a so-called “newer” macrolide, namely azithromycin or clarithromycin, the 
second choice being doxycycline.  In patients with COPD who received an antibiotic 
or steroids in the past three months, a “respiratory” quinolone (levofloxacin, gatiflox-
acin or moxifloxacin) is recommended, the second line choice being amoxicillin-
clavulanate plus a macrolide, or alternatively a second-generation cephalosporin plus 
a macrolide.  In cases of suspected macroaspiration, the first choice recommendation 
is amoxicillin-clavulanate plus a macrolide, the second choice being levofloxacin plus 
either clindamycin or metronidazole. 
 
2.2.4 Infectious Diseases Society of America (2000) 
 
In 2000, the Infectious Diseases Society of America (IDSA) updated their 1998 
guidelines for the treatment of CAP in adults (Infectious Diseases Society of America 
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2000).  Members of the guidelines committee are listed as co-authors of the report 
together with their affiliated institution, however there is no mention of the members’ 
area of specialty, so it is unclear whether primary care physicians were involved in 
the guidelines formulation process.   
The literature search strategy is not described, however, the committee used a 
grading system to assess the quality of the evidence provided by the research stud-
ies that they reviewed, as well as another grading system to classify the strength of 
the recommendations they made.  The grades for quality of evidence and strength of 
recommendation are explicitly stated with each recommendation presented in the 
guidelines.   
The IDSA guidelines emphasize the clinical importance of the decision to hos-
pitalize a patient or to treat on an outpatient basis.  They recommend the use of the 
clinical prediction rule for short-term mortality developed and validated by the Pneu-
monia Patient Outcome Research Team (Pneumonia PORT) (Fine et al. 1997) as a 
basis for deciding whether or not to hospitalize a patient. 
The IDSA guidelines state that the diagnosis of CAP is based on a combina-
tion of clinical and laboratory data, adding that a chest x-ray is usually necessary to 
establish the diagnosis.  The guidelines recommend that posteroanterior and lateral 
chest radiography be part of the routine workup of patient in whom CAP is consid-
ered a likely diagnosis and they discourage the initiation of empiric therapy without 
radiographic confirmation, although they acknowledge that obtaining chest x-rays 
“may not always be practical” (Infectious Diseases Society of America 2000, p. 370). 
For outpatients, sputum collection for Gram stain and culture are deemed op-
tional, however the IDSA panel makes a strong case in favour of establishing an etio-
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logic diagnosis for all patients.  For outpatients, the guidelines state that it is desirable 
to perform at least a Gram stain, with or without culture. 
Treatment recommendations emphasize a pathogen-directed antimicrobial 
therapy and prompt antimicrobial treatment.  Treatment recommendations are made 
based on suspected pathogens.  Recommendations for empiric antibiotic selection in 
the absence of an etiologic diagnosis, i.e. when Gram stain and culture are not diag-
nostic, are also made.  Drugs of first choice are recommended in “no particular order” 
and include doxycycline, a macrolide (erythromycin, clarithromycin or azithromycin) 
or a fluoroquinolone (levofloxacin, moxifloxacin or gatifloxacin).  For older patients or 
patients with co-morbidities, a fluoroquinolone is to be preferred.  When S. pneumo-
niae or H. influenzae are the suspected etiologic agents, amoxicillin-clavulanate or 
some second-generation cephalosporins (cefuroxime, cefpodoxime and cefprozil) are 
considered appropriate alternatives. 
 
2.3 Current best evidence in the treatment of community-acquired 
pneumonia 
 
The guidelines reviewed above differ in many respects:  in the composition of 
the guidelines committees, in the extent of reporting about the literature review and 
guidelines formulation process, in the use of classification systems to assess evi-
dence and rank recommendations, and in the content of the recommendations, be it 
in terms of diagnosis or treatment.  Table 1 summarizes the main features of the 
guidelines.   
A few common points also emerge from the above guideline review process:  
firstly, the importance of assessing the severity of disease and of the resulting deci-
sion to hospitalize was emphasized in all guidelines.  Furthermore, all guidelines ac-
25
 
 
knowledge – with varying degrees of openness - that there is little evidence on which 
to base treatment recommendations, particularly concerning ambulatory patients.  
However, in the end, in most cases it remains unclear on what basis the specific 
treatment recommendations were made and exactly what evidence was used to sub-
stantiate these recommendations. 
Consequently, the current project aims at identifying, evaluating and summa-
rizing the evidence available from RCT with respect to the treatment of CAP in adult 
and adolescent outpatients. 
 
 
  
Table 1: Characteristics and recommendations of clinical practice guidelines for the treatment of CAP 
Guideline Guideline formulation process Routine diagnostic 
studies recommended
Treatment of outpatients 
  Primary care 
physician on 
guidelines 
committee 
Search strat-
egy reported 
in detail 
Level of evidence 
stated for each 
recommendation 
Chest 
x-ray 
Gram 
stain 
Sputum 
culture 
Without modifying 
risk factors 
With modifying 
risk factors 
American Tho-
racic Society 
(2001) 
no no no yes no no macrolide (azi, clari) 
or doxycycline 
beta-lactam plus 
macrolide (azi, cla-
ri) or doxycycline 
British Tho-
racic Society 
(2001) 
yes yes yes no no no high-dose amoxicillin 
(500-1000mg po tid)   
2nd choice: ery or 
clari 
no separate rec-
ommendation 
Canadian 
Community-
Acquired 
Pneumonia 
Working 
Group (2000) 
? yes yes yes no no macrolide (ery, azi, 
clari)   2nd choice: 
doxycycline 
newer macrolide 
(azi, clari) or "respi-
ratory" quinolone 
(see section 2.2.3 
for details)  2nd 
choice: doxycycline 
Infectious Dis-
eases Society 
of America 
(2000) 
? no yes yes yes optional "in no particular or-
der":  macrolide (ery, 
azi, clari), doxycy-
cline, fluoroquinolone 
(levo, moxi, gati) 
fluoroquinolones 
(levo, moxi, gati) 
 
Abbreviations:  azi=azithromycin, clari=clarithromycin, ery=erythromycin, gati=gatifloxacin, levo=levofloxacin, moxi=moxifloxacin
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3. Objectives 
 
The objectives of this review are: 
1.  To assess and compare the efficacy of individual antimicrobial therapies with re-
spect to clinical, radiological and bacteriological outcomes in adult outpatients with 
CAP; 
2.  To assess and compare the efficacy of drugs across drug groups; 
3.  To make evidence-based practice recommendations if possible. 
4.  To assess the effect of drug schedule on adherence to treatment by carrying out 
an effectiveness analysis with open-label studies using different drug administration 
regimen. 
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4. Methods 
 
Randomized controlled trials (RCT) are considered the gold standard in clini-
cal research when it comes to establishing the efficacy of a treatment.  This favoured 
status is attributable to the fact that RCT most closely mirror a scientific experiment in 
the classical sense and are least susceptible to bias.  When properly conducted, they 
can lead to clear-cut conclusions about the relative efficacy of two treatments in a 
defined group of patients.  Consequently, we chose to focus our review exclusively 
on RCT. 
The following criteria were applied in selecting studies for inclusion into this 
review.  The rationale underlying the decision to use each criterion is detailed in the 
following sections. 
 
4.1 Study selection criteria 
4.1.1 Types of studies 
 
All randomized trials of antibiotics in adolescent and adult outpatients with 
CAP reporting on clinical parameters, cure rates or mortality were considered for in-
clusion.   
 
4.1.2 Types of participants 
Trials that included outpatients of either gender over 12 years of age in which 
pre-defined criteria for CAP were met as defined by the British Thoracic Society 
(2001) were included in this review.  
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4.1.3 Clinical Signs and Symptoms 
CAP in outpatients is defined as follows by the British Thoracic Society (2001): 
 
 Clinical definition, in the absence of a chest X-ray: 
-  Symptoms of an acute lower respiratory tract (LRT) infection (cough and at 
least one other LRT symptom); 
-  New focal chest signs on physical examination; 
-  at least one systemic feature (either a symptom complex of sweating, fevers, 
shivers, aches and pains and/or temperature >38.0°C). 
-  No other explanation for the illness, which is treated as pneumonia with an-
tibiotics. 
 
 Definition when a chest X-ray is available: 
-  Symptoms and signs consistent with an acute lower respiratory tract infec-
tion associated with new radiographic shadowing for which there is no other 
explanation (e.g. not pulmonary oedema or infarction) 
-  The illness is the primary clinical problem and is managed as pneumonia 
 
4.1.4 Types of interventions 
 
All double-blind randomized controlled comparisons of at least two antibiotics 
(or one antibiotic and a placebo) used to treat community-acquired pneumonia were 
included. Trials comparing two doses of the same drug were not included. 
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The perceived efficacy of antibiotics in pneumonia means that most of the 
available research deals with comparisons of two antibiotics. Comparisons involving 
intravenous drugs are usually carried out in a hospital setting. However, as this might 
occasionally be performed in an ambulatory setting, we did not a priori exclude stud-
ies dealing with intravenous drug applications.  
Trials allowing concurrent use of other medications such as antitussives, anti-
pyretics, bronchodilators, or mucolytics were included if they allowed equal access to 
such medications for patients in both arms of the trial. 
 
4.1.5 Types of outcome measures 
 
 When available, the following outcomes measures were documented in each 
of the selected studies: 
1.  Clinical response:  improvement of signs and symptoms.  Where possible, dura-
tion of clinical signs and symptoms were used as outcome measures.  We used a 
clinical definition of cure as the primary outcome since radiographic resolution lags 
behind clinical improvement (Macfarlane et al. 1984). 
2.  Radiologic response:  resolution or improvement of a new finding on chest x-ray 
after antibiotic therapy 
3.  Bacteriologic response: negative sputum culture in patients previously found to 
have causative pathogens in their sputum. 
4.  Frequency of hospitalization. 
5.  Mortality. 
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4.2 Search strategy for identification of studies 
 
The Cochrane Acute Respiratory Infections Group's trial register, The Coch-
rane Library, EMBASE and MEDLINE (1966-December 31st 2001) were searched 
using the following terms: COMMUNITY-ACQUIRED INFECTION, PNEUMONIA, 
RESPIRATORY TRACT INFECTION, ANTIBIOTICS.  Studies were also identified by 
checking the bibliographies of studies and review articles retrieved, and if necessary 
by contacting the first or corresponding authors of included studies. This search 
strategy yielded a total of 1417 references, some of which were double entries, due 
to the overlapping content of databases. 
 
4.3 Selection process 
 
Titles and abstracts of the identified citations were screened to exclude trials 
that clearly did not meet the inclusion criteria of the review.  If it was felt that a trial 
might possibly meet the inclusion criteria, the full paper was obtained for further 
study.  The most common reason for exclusion was that studies were conducted ex-
clusively in hospitalized patients.  Articles having passed this initial screen (34)  were 
then reviewed independently by two reviewers (myself (LMB) and TJMV) to deter-
mine whether they met the inclusion criteria of the review.  The selection process is 
shown graphically in Fig. 1. 
 
32
 
 
 
Figure 1: 
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Studies could be excluded for any one of the following reasons:  if they were 
not truly randomized, if they only compared two doses of the same substance, if the 
results were not reported separately for inpatients and outpatients, or if the indication 
for treatment consisted of a mix of diagnoses (most commonly:  acute bronchitis, ex-
acerbation of chronic bronchitis, and pneumonia) and the results were not reported 
separately for each diagnostic group.  Studies including only bacteriologically evalu-
able patients were excluded, because these patients are not necessarily typical of 
the spectrum encountered in primary practice.  In order to avoid that patients with 
bronchitis or other non-pneumonia lower respiratory tract infections be included, we 
excluded studies that did not confirm the diagnosis of CAP by chest x-ray.  Finally, 
studies were excluded if the total number of patients was less than 30, because be-
low this limit, the estimate of a binomial parameter (in this case, the proportion of pa-
tients cured or improved) becomes unstable (Armitage and Berry 1994).  Further-
more, when randomized controlled trials are too small, one can no longer safely as-
sume that all potential confounders (both documented and undocumented) have 
been controlled for by being distributed equally between the two treatment groups 
(Rothman and Greenland 1998).  For the primary analysis, we included only blinded 
RCT conducted in outpatients with CAP.  Trials in which allocation to treatment or 
control group was not concealed (open-label studies) that otherwise fulfilled all other 
inclusion and exclusion criteria were retained for a sub-group analysis concerning the 
effect of drug schedule on compliance (effectiveness analysis) (see Fig.2 and Sec-
tion 5.2.2). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Antibiotic comparisons  
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4.4 Data extraction 
 
The following data were extracted from each study whenever possible: 
- description of participants (outpatients over 12 years) 
- description of pathogens identified and their anti-microbial resistance profiles 
- description of intervention 
- description of control therapy 
- total number of participants in each arm of the trial 
- study setting 
- mean duration of symptoms in each arm of the trial 
- clinical, radiographic and bacteriologic cure rates in each arm of the trial 
- proportion of patients admitted to hospital in each arm of the trial 
- mortality rates in each arm of the trial 
- study sponsor 
 
The studies were assessed independently by 2 reviewers (LMB and TJMV) 
and disagreements were resolved by discussion and consensus.  There were no ir-
reconcilable disagreements. Reviewers were not blinded to the identity and affiliation 
of the study authors. 
 
4.5 Analyses 
 
For dichotomous outcome data, an estimate of the relative risk with approxi-
mate 95% confidence intervals was calculated.  This was done using the Cochrane 
Collaboration's Review Manager software, version 4.1.   
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5. Results 
 
5.1 Description of studies 
 
The characteristics of the studies included in the primary analysis as well as in 
the effectiveness analysis are shown in Table 2.  All studies except one (Peugeot et 
al. 1991) acknowledged the sponsorship of a corporate sponsor.   Two of the open-
label studies (Dautzenberg et al. 1992, Peugeot et al. 1991) included multiple diag-
noses but provided separate data for CAP patients, so it was possible to include 
these studies into the review.  Remarkably, four of the five open-label studies used 
different administration schedules for the drugs being tested within each study – for 
example, twice daily compared to four times daily.  The effect of these differences on 
compliance will be examined (see Section 5.2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2: Drug administration schedules and other study characteristics 
Regimen Study Drug 
Dose Frequency Duration 
Sponsor 
         
Multiple 
Diagnoses
        
Double-blind studies      
Clarithromycin 250 mg bid 14 d Anderson & 1991 
Erythromycin 500 mg qid 14 d Abbott no 
Clarithromycin 250 mg bid 7-14 d Chien & 1993 
Erythromycin 500 mg qid 7-14 d Abbott no 
Clarithromycin 250 mg bid 10 d Ramirez & 1999 
Sparfloxacin 200 mg* qd 10 d Rhône-Poulenc Rorer no 
         
Open-label studies      
Amoxi-Clav 500 mg + 125 mg tid 14 d Dautzenberg & 
1992 Roxithromycin 150 mg bid 14 d Roussel yes 
Amoxi-Clav 500 mg + 125 mg tid 10 d Higuera & 1996 § 
Cefuroxime 500 mg bid 10 d Glaxo Wellcome no 
Azithromycin 500 mg qd 3 d O’Doherty & 1998 
Clarithromycin 250 mg bid 10 d Pfizer no 
Erythromycin 400 mg qid 10 d Peugeot & 1991 
Ofloxacin 400 mg bid 10 d none declared yes 
Cefixime 400 mg qd 8-10 d Salvarezza & 1998
Roxithromycin 300 mg qd 8-10 d Hoechst Marion Roussel no 
* except Day 1:  400 mg loading dose    
§  Investigators blinded to administration schedules, patients not blinded & = et al.  
       
Abbreviations:       
qd = once daily     bid = twice daily     tid = three times a day     qid = four times a  day 
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5.1.1 Number of trials and trial size 
Three randomized controlled trials involving  a total of 622 patients aged 12 
years and older diagnosed with community-acquired pneumonia were included in the 
primary analysis (Anderson et al. 1991, Chien et al. 1993, Ramirez et al. 1999).   Five 
open-label randomized, but unblinded trials including a total of 405 patients and 
meeting all other inclusion/exclusion criteria were retained for sub-group analyses of 
effectiveness and compliance (Dautzenberg et al. 1992, Higuera et al. 1996, 
O’Doherty et al. 1998, Peugeot et al. 1991, Salvarezza et al. 1998).  The trials in the 
primary analysis included varying numbers of patients, the largest having 342 pa-
tients (Ramirez et al. 1999), the smallest 107 (Anderson et al. 1991).  The median 
trial size in the primary analysis was 173 patients, the mean size 207; in the effec-
tiveness analysis, the median size was 60 and the mean size 81. 
 
5.1.2 Diagnoses 
 
All three trials in the primary analysis exclusively enrolled patients with com-
munity-acquired pneumonia.  Two of the open-label trials (Dautzenberg et al. 1992, 
Peugeot et al. 1991) also included patients with other diagnoses, usually acute bron-
chitis or acute exacerbation of chronic bronchitis, but reported results separately for 
each diagnostic group, so that it was possible to extract data separately for pneumo-
nia patients.   
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5.1.3 Diagnostic criteria 
 
In all trials, the diagnosis of community-acquired pneumonia was based on 
clinical signs and symptoms as well as confirmation by radiographic findings in all 
patients.  The signs and symptoms used as diagnostic criteria included combinations 
of the following:  fever, chills, recent onset of productive cough, pleuritic chest pain, 
dyspnoea, pyrexia, tachypnoea, dullness to percussion, egophony, rales, localized 
reduced breath sounds and bronchial breath sounds. 
 
5.1.4 Out- vs Inpatients 
 
In all trials, patients were treated exclusively as outpatients. 
 
5.1.5 Patient inclusion and exclusion criteria 
 
Two trials (Anderson et al. 1991, Ramirez et al. 1999) in the primary analysis 
included only adult patients, one (Chien et al. 1993) also included adolescents (12 
years of age and older).  In the open-label trials, two trials reported including patients 
12 years of age and older (Higuera et al. 1996, O’Doherty et al. 1998) and one trial 
(Dautzenberg et al. 1992), patients as old as 90.  Only one of the studies used older 
age (>75 years) as an exclusion criterion (O’Doherty et al. 1998).  Overall, the trials 
excluded patients with conditions that could have affected the treatment or interfered 
with follow-up.  Exclusion criteria were reported in more or less detail in the various 
study reports.  The most common criteria reported were:  pregnancy and lactation, 
women not using adequate contraception (usually oral contraceptives or a barrier 
method), history of allergic reaction to the study drugs, recent treatment with or con-
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comitant use of an antimicrobial agent, concurrent medication with ergotamine, cyc-
losporin, antacids (except H2-antagonists) or digitalis, conditions affecting GI absorp-
tion, severe renal or hepatic impairment, terminal illness or conditions precluding 
study completion, infectious mononucleosis, HIV/AIDS, and prior participation in the 
study. 
 
5.1.6 Antibiotics 
The trials varied with respect to the antibiotics studied (see Fig. 2).  Two trials 
in the primary analysis (Anderson et al. 1991, Chien et al. 1993) studied the same 
antibiotic pair (clarithromycin and erythromycin).  The other trial (Ramirez et al. 1999) 
studied a different antibiotic pair, namely clarithromycin and sparfloxacin.  Antibiotic 
pairs studied in open-label trials were:  Dautzenberg et al. 1992: amoxiclav vs 
roxithromycin; Higuera et al. 1996: amoxiclav vs cefuroxime; O'Doherty et al. 1998: 
azithromycin vs clarithromycin; Peugeot et al. 1991: erythromycin vs ofloxacin; Salva-
rezza et al. 1998: cefixime vs roxithromycin (see Fig. 2). 
 
5.1.7 Methodological quality of included studies 
 
All three trials included in the primary analysis were randomized, double-blind 
studies comparing two antibiotics.  The extent of reporting was variable between 
studies.  None of the studies clearly stated the randomization method used.  None of 
the articles reported any test of effectiveness of the blinding procedures used.  Com-
pliance with treatment was assessed  by pill count in two studies (Anderson et al. 
1991, Chien et al. 1993); neither reported any difference in the number of pills re-
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maining between the two groups, however in the Chien et al. (1993) study, forty pa-
tients were excluded because they received "less than the minimum therapy" (7 
days) and these patients were distributed unevenly across the two groups (10 in the 
clarithromycin group and 30 in the erythromycin group).  The third study (Ramirez et 
al. 1999) reports having assessed patient compliance but does not state how.  Re-
garding co-interventions with other medications, most studies excluded patients 
whose co-medication included certain drugs such as other antibiotics, chemothera-
peutics or antiretrovirals.  Only one study (Chien et al. 1993) reported how many pa-
tients were excluded because of forbidden co-medication.  Withdrawals were re-
ported by all studies with varying degree of detail as to the reasons for withdrawal.  
The number of patients lost to follow-up was reported in all three studies.  Losses to 
follow-up appeared to be minor, amounting to a maximum of 10% of the initially ran-
domized patients. 
 
5.2 Study results 
5.2.1 Efficacy analysis (“primary analysis”) 
The success rates for each of the treatment arms of the three trials are shown 
in Table 3.  "Success" was defined as cure or improvement, be it clinical, bacterio-
logical or radiological, as assessed at a predefined follow-up visit that took place be-
tween 7 and 14 days after initiation of therapy.  None of the clinical, bacterial or radio-
logical success rates differed significantly among treatment arms within each of the 
studies, nor did they achieve clinical significance when the results of the two studies 
comparing clarythromycin with erythromycin (Anderson et al. 1991 and Chien et al. 
1993) were pooled together. 
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 To assess this, we pooled the outcomes of the two studies (Anderson et al. 
1991 and Chien et al. 1993) and calculated relative “risks” (RR) of success, be it 
clinical, bacteriological or radiological.  These analyses were performed using the 
Cochrane collaboration’s Review Manager Software Version 4.1, and illustrated 
graphically using the MetaView software, a subset of the Review Manager package 
(see Fig. 3, 4 and 5). 
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Table 3: Clinical, bacteriological and radiological cure rates 
 
 
Clinical success 
 
Bacteriological 
success 
Radiological suc-
cess 
Study Drug 
% 
n cured / 
N total % 
n cured / 
N isolated % 
n cured /   
N x-rayed 
 
Double-blind studies 
       
Clarithromycin 98% 63/64 89% 8/9 90% 55/61 Anderson & 1991 
Erythromycin 91% 39/43 100% 5/5 90% 38/42 
Clarithromycin 97% 89/92 88% 23/26 96% 88/92 Chien & 1993 
Erythromycin 96% 78/81 100% 17/17 96% 78/81 
Clarithromycin 83% 145/175 91% 74/81 Ramirez & 1999 
Sparfloxacin 80% 133/167 97% 64/66 
Not reported sepa-
rately 
          
Open-label studies       
Amoxi-Clav 63% 10/16 Dautzenberg & 
1992 Roxithromycin 93% 14/15 
No specimen taken Not reported sepa-
rately 
Amoxi-Clav 100% 55/55 93% 37/40 Higuera & 1996 
Cefuroxime 96% 49/51 94% 32/34 
Not reported sepa-
rately 
Azithromycin 94% 83/88 97% 31/32 O’Doherty & 1998 
Clarithromycin 95% 84/88 91% 32/35 
Not reported sepa-
rately 
Erythromycin 100% 13/13 92% 12/13* Peugeot & 1991 
Ofloxacin 100% 19/19 
Not reported sepa-
rately 94% 18/19* 
Cefixime 94% 28/30 95% 20/21 97% 28/29 Salvarezza & 
1998 Roxithromycin 100% 30/30 100% 19/19 90% 27/30 
*  one patient per group not followed up by x-ray     
       
Definitions of success:       
clinical success = cure or improvement      
radiological success =  resolution or improvement     
bacteriological success =  eradication of a previously identified pathological strain  
 
 
& = et al. 
 
 
  
Figure 3: Clinical success (pooled results)  
 
Figure 4: Bacteriological success (pooled results) 
 
ycin 
ycin 
 45
 
 
 
Figure 5: Radiological success (pooled results)  
 
 
ycin 
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It can be seen in figures 3 to 5 that all RR are close to the null value of 1, and 
all confidence intervals include or abut on 1, thereby indicating no significant differ-
ence in the respective success rates of treatment with clarythromycin and erythromy-
cin.  In the case of bacteriological success, there appears to be a tendency favouring 
erythromycin, however this does not achieve statistical significance. 
 
5.2.1.1 Comparisons across antibiotic groups 
 
The only comparison across antibiotic groups is provided by the study by Ra-
mirez et al. (1999), whereby a macrolide (clarithromycin) and a quinolone (sparflox-
acin) were compared.  Again, there was no significant difference in clinical or bacte-
riological success (see Table 3); radiological outcomes were not reported separately 
for the two treatment arms. 
 
5.2.1.2 Side-effects 
 
There were, however, significant differences in the occurrence of side-effects 
attributed to the study drug in the two studies comparing clarithromycin with erythro-
mycin (Anderson et al. 1991 and Chien et al. 1993) (Table 4).  In both cases, there 
were significantly more side-effects in the erythromycin group, the majority being gas-
trointestinal side-effects.  This was not, however, reflected in the rate of side-effects 
leading to withdrawal from the study, which was not significantly different across 
treatment arms. 
 
 
 Table 4: Reasons for exclusion from efficacy analyses and drug-related side-effects 
Regimen 
Reasons for exclusion from efficacy 
analyses Adverse events 
     
Less than  
minimum ther-
apy Loss to follow-up Total (drug-related) 
Leading to with-
drawals 
Study Drug 
Dose 
Fre- 
quency Duration
N / total N 
excluded % 
N / total N 
excluded % 
N / total N 
enrolled % 
N / total N 
enrolled % 
            
Double-blind studies            
Clarithromycin 250 mg bid 14 d 4/32 13% 0/32 0% 15/96* 16% 4/96 4% Anderson & 
1991 Erythromycin 500 mg qid 14 d 16/68 24% 1/68 1% 37/112* 33% 21/112 19% 
Clarithromycin 250 mg bid 7-14 d 20/41 49% 6/41 15% 34/133* 26% 6/133 5% Chien & 
1993 Erythromycin 500 mg qid 7-14 d 43/54 80% 5/54 9% 76/135* 56% 37/135 27% 
Clarithromycin 250 mg bid 10 d 10/48 $ 21% 7/48 15% 47/175 27% 10/175 6% Ramirez & 
1999 Sparfloxacin 200 mg* qd 10 d 10/42 $ 24% 6/42 14% 42/167 25% 14/167 8% 
            
Open-label studies            
Amoxi-Clav 500 mg  
+ 125 mg tid 14 d Not reported 67/242* 28% 21/242 9% 
Dautzenberg 
& 1992 ! 
Roxithromycin 150 mg bid 14 d Not reported 
13/477  3%  (both 
groups combined) 21/235* 9% 3/235 1% 
Amoxi-Clav 500 mg  
+ 125 mg 
tid 
 
10 d 
 
Not reported 
 
6/78 
 
8% 
 
Not reported 
 
Higuera & 
1996 § 
Cefuroxime 500 mg bid 10 d 
56#/162  35% 
(both groups 
combined) Not reported 3/84 4% Not reported  
Azithromycin 500 mg qd 3 d 1/101 1% Not reported 14/101 14% 0/101 0% O’Doherty & 
1998 Clarithromycin 250 mg bid 10 d 4/102 4% Not reported 13/102 13% 2/102 2% 
Erythromycin 400 mg qid 10 d Not reported  Not reported 4/28 14% 0/28 0% Peugeot & 
1991 ! Ofloxacin 400 mg bid 10 d Not reported Not reported 8/28 29% 2/28 7% 
Cefixime 400 mg qd 8-10 d Not reported  Not reported 0/30 0% 0/30 0% Salvarezza 
& 1998 Roxithromycin 300 mg qd 8-10 d Not reported Not reported 0/30 0% 0/30 0% 
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             Footnotes:
            
* = significant difference between treatment groups of a given study      
! = results are for all patients in study (all diagnoses combined), results for pneumonia were not reported separately   
§  = investigators blinded, patients not blinded      
$  = includes "protocol deviations" (not  further specified)      
# = "clinically unevaluable" (less than 3 days of therapy, resistant pathogen in pre-treatment culture, other protocol deviation) 
 
& = et al.  
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5.2.1.3 Bacterial pathogens 
 
Various bacterial pathogens were identified with varying frequency across 
studies (see Table 5).  The proportion of samples yielding an identifiable pathogen 
ranged from 19% (Anderson et al. 1991) to 43% (Ramirez et al. 1999).   Anderson et 
al. (1991) reported on a majority of cases being positive for Haemophilus influenzae 
(62% of positive cultures) with S. pneumoniae (18%) being second most common, 
whereas Chien et al. (1993) predominantly identified Streptococcus pneumoniae as 
the causative organism in 56% of cultures, with H. influenzae taking second place at 
40%.  On the contrary, Haemophilus parainfluenzae (31%) was the most commonly 
identified pathogen in the study by Ramirez et al. (1999), with H. influenzae (23%) in 
second place. 
 Table 5: Eradication rates and proportional importance of bacterial pathogens 
 
Pathogens as % of all isolates 
Gram-negative aerobes Gram-positive aerobes Study 
Bacterial isolates:     
n isolated/Total N 
sampled H. influenzae H. parainfluenzae H. parahaemolyticus M. catarrhalis S. Pneumoniae Staph. Aureus 
               
Double-blind studies               
Anderson &1991 39/208 19% 24/39 62% 5/39 13% ****** ****** 3/39 8% 7/39 18% ****** ****** 
Chien & 1993 43/173 25% 17/43 40% 2/43 5% ****** ****** ****** ****** 24/43 56% ****** ****** 
Ramirez & 1999 147/342 43% 34/147 23% 45/147 31% 8/147 5% ****** ****** 18/147 12% 5/147 3% 
               
Open-label studies               
Dautzenberg & 1992 *****        Not tested         ****** 
Higuera & 1996 § 97/162 60% 17/97 18% ******* ******* ******* 37/97 38% ******* 
O’Doherty & 1998 66/203 33% 34/67 51% ******* ******* 9/67 13% 6/67 9% 2/67 3% 
Peugeot & 1991 6/32 19% 3/6 50% ******* ******* ******* 3/6 50% ******* 
Salvarezza & 1998 37/58 64% 3/37 8% ******* ******* 3/37 8% 26/37 70% ******* 
               
§  = investigators blinded, patients not blinded 
& = et al.            
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5.2.1.4 Serologically identified pathogens 
 
Only two of the three studies carried out serologic tests to identify putative 
pathogens (Anderson et al. 1991 and Chien et al. 1993; see Table 6).  In both these 
studies, the most frequently identified pathogen was Mycoplasma pneumoniae, which 
represented 69% (Anderson et al. 1991) and 74% (Chien et al. 1993) of positive se-
rology results.  Chlamydia pneumoniae accounted for the remainder with 38% 
(Anderson et al. 1991) and 26% (Chien et al. 1993) respectively.  There were no 
samples positive for Legionella pneumoniae or for Chlamydia psittaci in either study. 
 
 
Table 6: Proportional importance of serologically identified pathogens 
Serology:       positive serologic tests Study 
n positive /  
total N tested
Mycoplasma 
pneumoniae
Chlamydia 
pneumoniae
Legionella 
pneumoniae 
Chlamydia 
psittaci 
           
Double-blind studies         
Anderson & 1991 16/208° 8% 11/16 69% 6/16 38% ******* ******* 
Chien & 1993 27/173 16% 20/27 74% 7/27 26% ******* ******* 
Ramirez & 1999 *****        Not tested         ****** 
           
Open-label studies           
Dautzenberg & 1992 *****        Not tested         ****** 
Higuera & 1996 *****        Not tested         ****** 
O’Doherty & 1998 7/203 3% 4/7 57% 1/7 14% 2/7 29% ******* 
Peugeot & 1991 2/32 6% ******* 2/2 100% ******* ******* 
Salvarezza & 1998 10/60 17% 5/10 50% ******* ******* 5/10 50%
           
° = one patient was positive for both M. pneumoniae and C. pneumoniae 
& = et al.   
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5.2.2 Effectiveness analysis (open-label studies) 
 
All of the trials in the effectiveness analysis were randomized open-label or 
single-blind studies comparing two antibiotics.  In one of the studies (Higuera et al. 
1996), the investigator were blinded to the treatment insofar as the drugs were dis-
pensed by a pharmacist or study coordinator and the patients were instructed not to 
discuss the frequency of dosing with the investigator.  All studies except one (Salva-
rezza et al. 1998) compared different dosage regimen (see Table 2), whereby one 
drug was given at a higher frequency (twice vs four times daily; Peugeot et al. 1991); 
in some cases, one of the drugs was also given over a longer time period (ten vs 
three days; O’Doherty et al. 1998).  Only two of the studies (Salvarezza et al. 1998, 
Higuera et al. 1996) clearly stated the randomization method used.  Compliance with 
treatment was assessed by pill count as well as urine testing in one of the studies 
(Higuera et al. 1996).  Most studies excluded patients who received co-medication 
with certain drugs, such as other antibiotics, chemotherapeutics or anti-retrovirals.  
Only one study (O’Doherty et al. 1998) reported how many patients were excluded 
because of forbidden co-medication.  One other study (Higuera et al. 1996) reported 
that patients were excluded on these grounds but did not report how many patients 
were thereby excluded.  None of the studies reported losses to follow-up; therefore, it 
is not possible to quantify the extent of the problem.  In most studies, withdrawals 
were reported along with the reasons for withdrawal.   
 
5.2.2.1 Effect of administration schedule on adherence to treatment 
 It would be reasonable to assume that a higher frequency and longer duration 
of drug administration would impose a burden on patients that could result in de-
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creased compliance.  In order to test this hypothesis, I extracted data on losses to 
follow-up and patients receiving “less than minimum therapy” for all open-label stud-
ies (see Table 4).  Unfortunately, four studies (Higuera et al. 1996, O’Doherty et al. 
1998, Peugeot et al. 1991, Salvarezza et al. 1998) did not report on losses to follow-
up and the only study that did (Dautzenberg et al. 1992) pooled the results of both 
treatment groups together, making it impossible to determine whether there was any 
differential loss to follow-up across treatment groups.  Likewise, three studies 
(Dautzenberg et al. 1992, Peugeot et al. 1991, Salvarezza et al. 1998) did not report 
how many patients received “less than minimum therapy”.  One of the studies that did 
(Higuera et al. 1996) reported combined results for both treatment groups.  Finally, 
O’Doherty et al. (1998) reported results separately for both treatment groups, and 
these were not significantly different from each other. 
 Therefore, due to inadequate reporting, it was not possible to draw any con-
clusions about the effect of administration schedules on compliance. 
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6. Discussion 
 
6.1 Evidence 
 
The overwhelming feature of this systematic review is the utter paucity of rele-
vant studies that could be identified and included in the review.  Given this current 
state of affairs, it is not possible to make solid evidence-based recommendations for 
the treatment of community-acquired pneumonia in ambulatory outpatients.  One im-
portant reason for this lack of evidence is that a large number of the trials originally 
identified were conducted in hospitalized patients and were therefore excluded be-
cause they were not directly relevant to the treatment of ambulatory patients.   
 Another remarkable feature of the collected studies is the incompleteness of 
the reporting.  This further complicated matters by making it difficult or impossible to 
compare and combine the available results in a meaningful way.  Finally, the hetero-
geneity of the antibiotic pairs studied precludes pooling study results quantitatively. 
 
6.2 Methods 
 
It could be argued that the inclusion/exclusion criteria for this review were too 
strict and that this is the reason why so few studies were retained.  I do, however, 
believe that the criteria I applied were necessary in order to validly address the ques-
tion of the efficacy of treatment of CAP in ambulatory patients.  In particular, it could 
be argued that the decision to exclude studies based on size is not desirable, since 
one aim of the review is to pool results and that each study therefore would contrib-
ute some information.  I felt, however, that this criterion was necessary to exclude 
studies where the number of patients with pneumonia was so small that randomiza-
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tion could no longer be expected to achieve a balanced distribution of confounders, 
both known and unknown, across study groups.  Finally, arguing retrospectively, it 
can be seen that dropping size as an exclusion criteria would not have made much 
difference to the results obtained, as the three excluded studies would have contrib-
uted a total of 23 (Fong et al. 1995), 6 (Gris 1996) and 8 (Tilyard and Dovey 1992) 
patients respectively, thereby only increasing the size of the primary analysis group 
by 5.9 % (from 622 to 659).  Furthermore, the study by Fong et al. (1995) being an 
open-label study, it would only have been included in the effectiveness analysis. 
As for the requirement that the diagnosis of CAP be confirmed by a chest ra-
diograph, I felt that this was necessary to avoid diagnostic misclassification, which 
could have led to inclusion of patients with bronchitis into the review. 
 
6.3 Implications for practice 
Currently available evidence from RCT is insufficient to make truly evidence-
based recommendations for the treatment of community-acquired pneumonia.  Indi-
vidual study results do not reveal significant differences in efficacy between various 
antibiotics and antibiotic groups.  Until better evidence becomes available, practitio-
ners should favour shorter course therapies with lower drug costs whenever possible 
as a means of enhancing compliance and reducing expenses, while still taking into 
account the regional resistance profiles prevalent in their area of practice as well as 
the characteristics of each patient.  
National guidelines may provide additional decision-making support, but clini-
cians should keep in mind that current guideline recommendations for the treatment 
of CAP in ambulatory patients are based on very scanty evidence. 
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6.4 Implications for research 
Multi-drug, multi-drug-group double-blind comparisons using similar admini-
stration schedules and carried out in the ambulatory setting are needed to provide 
the evidence necessary for practice recommendations if these are to be applicable to 
outpatient treatment.  Study conditions should ensure that diagnosis and manage-
ment of patients with community-acquired pneumonia are as similar as possible to 
real practice, while still ensuring that the study question is addressed in a valid way.  
Whether a study of this extent and character would find the necessary funding is, 
however, doubtful. 
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7. Summary 
 
BACKGROUND 
Community-acquired pneumonia (CAP) is a common condition representing a 
significant disease burden for the community, particularly for the elderly. It also con-
tributes significantly to health care expenditures and antibiotic use, which is associ-
ated with well-known problems of resistance.  Although many studies have been pub-
lished concerning CAP and its treatment, there is no concise summary of the avail-
able evidence and only few guidelines that can help clinicians in choosing the most 
appropriate antibiotic 
 
OBJECTIVES 
The goal of this study was to summarize the evidence currently available from 
randomized controlled trials (RCT) concerning the efficacy of antiobiotic treatment of 
CAP in ambulatory adolescent and adult patients and to formulate evidence-based 
practice recommendations. 
 
SEARCH STRATEGY 
The Cochrane Acute Respiratory Infections Group's trial register, The Coch-
rane Library, MEDLINE and EMBASE were searched using the following terms: 
COMMUNITY-ACQUIRED INFECTION, PNEUMONIA, RESPIRATORY TRACT IN-
FECTION, and ANTIBIOTICS up to and including December 31st 2001. Studies were 
also identified by checking the bibliographies of the articles retrieved.  
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SELECTION CRITERIA 
All randomized controlled trials in which one or more antibiotics were tested for 
the treatment of CAP in ambulatory adolescent or adult patients were considered for 
inclusion.  Studies testing one or more antibiotics and reporting the diagnostic criteria 
used in selecting patients as well as the clinical outcomes achieved were included.  
No language restrictions were applied.   
 
DATA COLLECTION & ANALYSIS 
Study reports were assessed and data extracted using predefined criteria.  Au-
thors of studies were contacted as needed to resolve any ambiguities in the study 
reports.  The data were analyzed using the Cochrane Collaboration's Review Man-
ager 4.1 Software.  
 
MAIN RESULTS 
Three randomized controlled trials involving a total of 622 patients aged 12 
years and older diagnosed with community-acquired pneumonia were included.  The 
quality of the studies and of the reporting was variable.  A variety of clinical, radio-
logical and bacteriological diagnostic criteria and outcomes were reported.  Overall 
there was no significant difference in the efficacy or effectiveness of the various anti-
biotics under study.  However, the available evidence is too incomplete to form a 
solid basis for making evidence-based recommendations. 
 Five open-label studies were retained in order to carry out an effectiveness 
analysis to assess the impact of different drug regimen on patient compliance.  Unfor-
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tunately, the reporting of losses to follow-up was so incomplete that it precluded 
drawing any conclusions about this question. 
 
CONCLUSIONS 
Currently available evidence from randomized controlled trials is insufficient to 
make evidence-based recommendations for the treatment of community-acquired 
pneumonia.  Pooling of study data was limited by the very low number of studies, by 
their heterogeneity and by incomplete reporting of study results.  Individual study re-
sults do not reveal significant differences in efficacy between various antibiotics and 
antibiotic groups.  Multi-drug comparisons using similar administration schedules are 
needed to provide the evidence necessary for practice recommendations.  Until bet-
ter evidence becomes available, practitioners should favour shorter course therapies 
with lower drug costs whenever possible as a means of enhancing compliance and 
reducing expenses, while still taking into account the regional resistance profiles 
prevalent in their area of practice as well as the clinical course of each patient. 
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8. Zusammenfassung (Summary in German) 
 
EINLEITUNG  
Die ambulant erworbene Pneumonie (AEP) ist eine häufige, oft schwere Er-
krankung von großer Bedeutung für die Bevölkerung, die insbesondere für ältere Pa-
tienten kompliziert verlaufen kann. Die übliche Behandlung der AEP besteht in der 
Gabe von Antibiotika. Dies trägt u.a. zur Zunahme von Antibiotikaresistenzen bei. 
Obwohl bereits viele Studien zur Behandlung der AEP veröffentlicht wurden, gibt es 
keine aktuelle Zusammenfassung der vorhandenen Evidenz und nur einzelne Leitli-
nien, die den behandelnden Arzt bei der Wahl eines Antibiotikums unterstützen. 
 
ZIEL 
Ziel dieser Studie war es, die vorhandene Evidenz randomisierter, kontrollier-
ter Studien (RCT) bzgl. der AEP Behandlung bei ambulanten Patienten zusammen-
zufassen und ggf. eine evidenz-basierte Leitlinie/Therapieempfehlung zu formulieren. 
 
METHODEN 
Eine umfassende elektronische und manuelle Literatursuche wurde durchge-
führt mit dem Ziel, alle RCT zu identifizieren, in denen zwei oder mehr Antibiotika für 
die Behandlung der AEP geprüft wurden.  Die Cochrane Library, MEDLINE und EM-
BASE (bis einschließlich 31.12.2001) wurden mit folgenden Suchbegriffen durch-
sucht: COMMUNITY-ACQUIRED INFECTION, PNEUMONIA, RESPIRATORY 
TRACT INFECTION und ANTIBIOTICS. Die Literaturverzeichnisse der ausgewählten 
Studien wurden auf weitere relevante Artikel durchsucht. Alle RCT, die ein oder meh-
rere Antibiotika prüften und deren diagnostische Kriterien und Outcomes dargestellt 
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waren, wurden eingeschlossen. Es wurden keine Spracheinschränkungen verwen-
det. Die jeweiligen Artikel wurden begutachtet und deren Inhalt mit der Software „Re-
view Manager“ (Version 4.1) in standardisierter Form extrahiert.   
 
ERGEBNISSE 
Es wurden drei Studien gefunden, die die Einschlusskriterien  erfüllen. Die 
Studien umfassten insgesamt 612 Patienten mit einer ambulant erworbenen Pneu-
monie. Verschiedene klinische, bakteriologische und radiologische Endpunkte wur-
den berichtet. Die vorhandene Evidenz wurde zusammengefasst und beurteilt. Ins-
gesamt gab es keinen wesentlichen Unterschied zwischen den verschiedenen Prä-
paraten bezogen auf die Wirksamkeit oder damit verbundene unerwünschte Arznei-
mittelwirkungen. Jedoch ist die vorhandene Evidenz zu unvollständig, um eine ein-
heitliche evidenz-basierte Leitlinie oder Therapieempfehlungen formulieren zu kön-
nen. 
Fünf randomisierte Studien ohne Verblindung wurden in einer Effektivitätsana-
lyse beurteilt, um den Einfluss verschiedener Therapiepläne auf die Patientencompli-
ance zu evaluieren. Leider wurden Therapieabbrüche so unvollständig berichtet, 
dass es unmöglich war, Schlussfolgerungen aus diesen Daten zu ziehen. 
 
SCHLUSSFOLGERUNGEN 
 Die zur Zeit vorhandene Evidenz von randomisierten kontrollierten Studien 
ambulanter Patienten reicht nicht aus, um evidenz-basierte Therapieempfehlungen 
zu formulieren. Die Zusammenfassung der Studienergebnisse wurde durch die nied-
rige Studienzahl, die Heterogenität der Studien und die Unvollständigkeit der Studi-
enberichte stark eingeschränkt. Einzelne Studienergebnisse zeigen keinen signifikan-
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ten Unterschied in der Wirksamkeit der verschiedenen Antibiotika. Randomisierte 
kontrollierte Blindstudien, in denen mehrere Antibiotika aus verschiedenen Gruppen 
miteinander verglichen werden, sind erforderlich, um evidenz-basierte Therapieemp-
fehlungen formulieren zu können. Bis solche Evidenz zur Verfügung steht, sollten 
behandelnde Ärzte kurze Therapien mit geringen Kosten bevorzugen. Dabei sollten 
die Charakteristika der einzelnen Patienten und, soweit vorhanden, regionale Resi-
stenzprofile berücksichtigt werden. 
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9. Appendices 
 
9.1 List of abbreviations 
 
   
 
CAP  Community-acquired pneumonia 
COPD Chronic obstructive pulmonary disease 
DRSP Drug-resistant Streptococcus pneumoniae 
ICU  Intensive care unit 
LRT  Lower respiratory tract 
  RCT  Randomized controlled trial 
  RR  Relative risk 
 
  qd  once daily 
  bid  twice daily 
  tid  three times a day 
  qid  four times a day 
  po  by mouth 
  iv  intravenous 
   
  MMK  Prof. Michael M. Kochen 
  TJMV  Prof. Theo V.M. Verheij 
  LMB  Lise M. Bjerre 
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